# Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

> **NCT04238390** · PHASE3 · WITHDRAWN · sponsor: **The University of Queensland**

## Conditions studied

- Bacteremia Caused by Gram-Negative Bacteria

## Interventions

- **DRUG:** Ceftolozane-Tazobactam
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT04238390
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The decision to withdraw the study was made due to delayed logistics of the supply chain of ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt because of the COVID-19 pandemic.
- **Last updated:** 2022-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238390, "Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04238390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*